Literature DB >> 1932288

Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.

J M Lusher1.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1932288     DOI： 10.1007/bf01703244

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

1.  Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis.

Authors:  P M Mannucci; M Colombo
Journal:  Thromb Haemost       Date:  1989-06-30       Impact factor: 5.249

2.  Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group.

Authors:  P M Mannucci; K Schimpf; D B Brettler; N Ciavarella; M Colombo; F Haschke; K Lechner; J Lusher; G Weissbach
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

3.  Virucidal treatment of clotting factor concentrates.

Authors:  P M Mannucci; M Colombo
Journal:  Lancet       Date:  1988-10-01       Impact factor: 79.321

4.  Measurement of factor VIII inhibitors.

Authors:  C K Kasper
Journal:  Prog Clin Biol Res       Date:  1984

5.  Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII.

Authors:  J Haimovich; H M Davis; A B Schreiber
Journal:  Semin Hematol       Date:  1990-04       Impact factor: 3.851

6.  Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.

Authors:  K Schimpf; P M Mannucci; W Kreutz; H H Brackmann; G Auerswald; N Ciavarella; J Mösseler; V DeRosa; B Kraus; C Brueckmann
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

7.  Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.

Authors:  J M Lusher; P M Salzman
Journal:  Semin Hematol       Date:  1990-04       Impact factor: 3.851
  7 in total
  4 in total

Review 1.  Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.

Authors:  G Bray
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

2.  Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure.

Authors:  Gilbert C White
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

3.  Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.

Authors:  A Yoshioka; K Fukutake; J Takamatsu; A Shirahata
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 4.  Immunogenicity of Current and New Therapies for Hemophilia A.

Authors:  Alessandra N L Prezotti; Jéssica O Frade-Guanaes; Gabriela G Yamaguti-Hayakawa; Margareth C Ozelo
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.